Frailty helps predict mortality risk associated with progressive liver cirrhosis: Study
Canada: In a new study conducted by Sarah Wang and team, frailty was found to be an independent predictor of progression of cirrhosis or mortality, as well as unnecessary hospitalization in both compensated and decompensated cirrhosis patients. The findings of this study were published in the journal Hepatology.
The Liver Frailty Index (LFI) is a widely known and well-studied instrument for assessing frailty in cirrhotic individuals. The LFI, which includes grip strength, chair stands, and balance testing, has been linked to an increase in mortality in patients awaiting a liver transplant. The goal of this study was to learn more about frailty in cirrhosis by investigating the association between the LFI and the risk of (1) death, (2) cirrhosis progression, and (3) unplanned hospitalizations in both compensated and decompensated illness.
Cirrhotic adults from four sites in North America and one in India were included in the study. The LFI was used to assess frailty at baseline, and it was classified as robust (LFI 3.2), prefrail (LFI 3.2-4.5), or frail (LFI > 4.5). Cirrhosis progression was defined as an increase in clinical stage (from 1 to 5) from baseline using the D'Amico classification. Multivariate regression models were used to examine factors related to progression, death, and hospitalizations, with transplants serving as a competing risk.
The results of this study stated as follow:
1. In all, 822 cirrhotic individuals were included in the study.
2. The average MELD (Model for End-Stage Liver Disease) score was 15.5 6.0. After controlling for age, gender, and MELD score, being frail vs robust was associated with a higher risk of progression to the next cirrhosis stage or mortality (HR, 2.45) and an increased risk of unplanned hospitalizations (2.32).
3. Patients with decompensated cirrhosis had similar HRs.
In conclusion, In both compensated and decompensated cirrhosis, frailty has shown to be an independent predictor of cirrhosis progression or mortality, as well as unscheduled hospitalizations.
Reference:
Wang S, Whitlock R, Xu C, Taneja S, Singh S, Abraldes JG, Burak KW, Bailey RJ, Lai JC, Tandon P. Frailty is associated with increased risk of cirrhosis disease progression and death. Hepatology. 2022 Mar;75(3):600-609. doi:10.1002/hep.32157. Epub 2021 Dec 5. PMID: 34528267.
